advertisement

WGA Rescources

Abstract #74715 Published in IGR 19-1

Glaucoma drug therapy in pregnancy: literature review and Teratology Information Service (TIS) case series

Pellegrino M; D Oria L; De Luca C; Chiaradia G; Licameli A; Neri C; Nucci M; Visconti D; Caruso A; De Santis M
Current drug safety 2018; 13: 3-11


BACKGROUND: there are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications. METHOD: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as part of multidrug therapy. We selected a control group of 187 healthy pregnant women. RESULTS: topical use of timolol alone or timolol in combination with other antiglaucoma medications don't influence pregnancy or fetal/neonatal outcomes. CONCLUSION: beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.

Teratology Information Service. Department of Obstetrics and Gynecology, Fetal Diagnosis and Therapy Unit, Catholic University of Sacred Heart, Policlinico A. Gemelli Hospital, Rome. Italy.

Full article

Classification:

11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
15 Miscellaneous



Issue 19-1

Change Issue


advertisement

Oculus